Low success rates in clinical trials remain a major challenge in drug development. We leverage our expertise and bring human genetic evidence to therapeutic target discovery and validation. We envision nominating therapeutic targets for disease subtypes based on their underlying biology.
We identified an allelic series of rare protein-altering variants in ANGPTL7 that lower intraocular pressure and protect against glaucoma, highlighting ANGPTL7 as a therapeutic …
We analyzed the genetic basis of 35 blood and urine biomarkers in UK Biobank. We revealed that genetic effects on biomarkers inform the genetic basis of disease.
We introduce "hypometric genetics," an approach to investigate the genetic basis of binarized traits representing the presence of below-the-limit-of-quantification (BLQ) quality …